Analytics, not advice. Rankings and scores describe past performance and are not recommendations.
Uncategorised
BAJAJ FINSERV HEALTHCARE FUND - DIRECT - GROWTH
Bajaj Finserv Mutual Fund · Managed by Siddharth Chaudhary; Vinay Bafna; Bharat Hegde
47slipping
Latest NAV
₹11.9410
as of 07 Aug 2026
AUM
—
Expense ratio
0.66%
as of 30 Jun 2026
Inception
14 May 2026
FundScore
47/100slipping
Rank #530 of 1007 · top 53%
A daily percentile of this fund’s past performance within its SEBI category — analytics, not advice, and not a prediction or recommendation.
Trailing returns
Annualised returns to the latest NAV. Refreshed nightly.
1M
7.25%
3M
13.42%
6M
26.11%
1Y
23.40%
3Y CAGR
—
5Y CAGR
—
Since incep.
11.14%
Fund details
- Fund manager
- Siddharth Chaudhary; Vinay Bafna; Bharat Hegde
- Riskometer
- Very High Risk
- Type
- Open Ended
- Portfolio turnover
- 41%
- Volatility (3Y)
- 13.6%
- Rating (external)
- —
Investment objective
The objective of the Scheme is to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
NAV history
Zoom and pan · ranges from 1M to since-inception.
Rolling returns
Every 30-day step. The true distribution, not cherry-picked.
Rank history
Percentile within category over the last 2 years.
FundScore components
Pro-only breakdown of consistency, recency, and volatility scores.
Upgrade to Pro to see the raw drivers behind this scheme's FundScore label.
Pro
Market-cap distribution
Large / mid / small / micro-cap split of this fund's equity holdings, from its latest look-through portfolio. Shown as a share of classified equity.
Large cap33.1%
Mid cap20.8%
Small cap46.1%
Stock holdings
Latest portfolio disclosure for this scheme. Snapshot as of 30 Jun 2026.
Divi's Laboratories Limited
equity
8.40%
Apollo Hospitals Enterprise Limited
equity
6.71%
Aurobindo Pharma Limited
equity
6.52%
Sun Pharmaceutical Industries Limited
equity
6.36%
Piramal Pharma Limited
equity
6.04%
Rubicon Research Limited
equity
6.02%
Torrent Pharmaceuticals Limited
equity
5.26%
Neuland Laboratories Limited
equity
4.59%
Emcure Pharmaceuticals Limited
equity
4.36%
Max Healthcare Institute Limited
equity
4.16%
Fortis Healthcare Limited
equity
3.25%
Zydus Wellness Limited
equity
2.82%
IPCA Laboratories Limited
equity
2.43%
Vijaya Diagnostic Centre Limited
equity
2.36%
Senores Pharmaceuticals Limited
equity
2.29%
Navin Fluorine International Limited
equity
2.17%
Laurus Labs Limited
equity
2.14%
Shaily Engineering Plastics Limited
equity
2.03%
Sanofi Consumer Healthcare India Limited
equity
1.80%
Glenmark Pharmaceuticals Limited
equity
1.73%
GlaxoSmithKline Pharmaceuticals Limited
equity
1.65%
Dr. Lal Path Labs Limited
equity
1.64%
Bajaj Finserv Money Market Fund-Direct Plan-Growth
other
1.48%
Zydus Lifesciences Limited
equity
1.40%
Biocon Limited
equity
1.35%
Abbott India Limited
equity
1.25%
MedPlus Health Services Limited
equity
1.18%
Krishna Institute Of Medical Sciences Limited
equity
1.15%
Medi Assist Healthcare Services Limited
equity
1.04%
Eris Lifesciences Limited
equity
1.01%